Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Dylan Finley

UBS · covers Healthcare

Period: Reporting period mapped to calendar 2025 Q4.

Limited coverage. Only 3 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.
Questions
3on tracked calls
Challenge rate
0%none of 3 questionsLimited sample
Companies
2questioned at least once
Reporting periods
1with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 3 of 3 questions from 2 companies

SOLVSolventum2 questions · 1 reporting period · 0 of 2 challenging
SOLV company page →

Calendar 2025 Q4

how much of that was volume expansion versus price capture related to or not related to tariffs

Revenue GrowthPricingTranscript · FY2025 Q4 →
Show response

CEO attributed dental outperformance primarily to new products and secondarily to backorder recovery (one-time); no extraordinary pricing; market stable to slightly improving.

what should we contemplate regarding the phasing of those -- both the costs going into the restructuring and the timing of the benefits

MarginCost PressureTranscript · FY2025 Q4 →
Show response

CFO confirmed $500M cost takeout spans 2026-2030; benefits start in 2026 but majority in 2027+; comprehensive across operating structure, procurement, manufacturing, global footprint, systems, automation.

ALGNAlign Technology1 question · 1 reporting period · 0 of 1 challenging
ALGN company page →

Calendar 2025 Q4

how was that contemplated into the one to 2% ASP decline that you're forecasting for the year?

PricingProduct LaunchTranscript · FY2025 Q4 →
Show response

John explained NOAA has no ASP impact because full revenue is recognized upfront (no deferral for refinements). Refinements come over time as incremental. Volume and ASP guidance already contemplates NOAA rollout.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
SOLV Solventum2—Rate withheld: fewer than 3 questions
ALGN Align Technology1—Rate withheld: fewer than 3 questions
  • SOLV
    Solventum · 2 questions
    —rate withheld: under 3 questions
  • ALGN
    Align Technology · 1 question
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2025 Q430%none of 3 questions2
  1. 2025 Q43 questions · challenge rate 0% (none of 3 questions) · 2 companies

Topics

Topics tagged on this analyst’s questions.

  • Pricing2
  • Product Launch1
  • Revenue Growth1
  • Margin1
  • Cost Pressure1